Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives (Q37686735)

22 August 2017

title

Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives (English)

1 reference

22 August 2017

Reinhard Klingel

1 reference

22 August 2017

Andreas Heibges

series ordinal

1 reference

22 August 2017

Cordula Fassbender

series ordinal

1 reference

22 August 2017

publication date

1 December 2009

1 reference

Atherosclerosis. Supplements

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

129-132

1 reference

Influence of plasma immunoglobulin level on antibody synthesis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Treatment of myasthenia gravis by immunoadsorption of plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Long-term treatment of refractory myasthenia gravis with immunoadsorption

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Long-term treatment of myasthenia gravis with immunoadsorption

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

1 reference

7 January 2021

Clinical implications of neuropathological findings in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971827-6

7 January 2021

10.1016/S1567-5688(09)71827-6

Identifiers

DOI

1 reference

22 August 2017

1 reference